Related Experiment Video

Updated: Jul 20, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways

Atefe Rahmati1,2, Alireza Mafi3, Omid Vakili4

  • 1Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Annals of Hematology
|August 1, 2023
PubMed

Insights

Non-coding RNAs (ncRNAs) play a crucial role in leukemia drug resistance by regulating key molecular mechanisms and signaling pathways. Understanding these ncRNAs is vital for developing effective leukemia treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Leukemia treatment efficacy relies on timely diagnosis and overcoming drug resistance.
  • Mechanisms of drug resistance include altered drug uptake/metabolism and epigenetic changes.
  • Non-coding RNAs (ncRNAs) are key regulators of cellular processes and disease development.

Purpose of the Study:

  • To comprehensively review the role of ncRNAs in the development of leukemia drug resistance.
  • To elucidate the specific molecular mechanisms and signaling pathways influenced by ncRNAs in this context.

Main Methods:

  • Literature review of studies investigating ncRNAs and leukemia drug resistance.
  • Analysis of molecular mechanisms (e.g., drug efflux, metabolism, epigenetics) regulated by ncRNAs.
  • Examination of signaling pathways modulated by ncRNAs in leukemia.

Main Results:

  • ncRNAs are central regulators orchestrating various drug resistance mechanisms in leukemia.
  • Specific ncRNAs have been identified to modulate key pathways involved in chemoresistance.
  • ncRNAs influence processes like cell proliferation, apoptosis, and immune responses relevant to drug resistance.

Conclusions:

  • ncRNAs are significant contributors to the initiation and progression of leukemia drug resistance.
  • Targeting ncRNAs presents a potential therapeutic strategy for overcoming chemoresistance in leukemia.
  • Further research into ncRNA functions can lead to novel leukemia treatment approaches.
Keywords:
ApoptosisAutophagyDrug resistanceHematologic neoplasmsLeukemiaNoncoding RNAs

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.8K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
64.0K